Vivoryon Therapeutics Showcases Kidney Disease Breakthrough
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) is making promising strides in the clinical stage biotechnology sector. The company is dedicated to discovering and developing small molecule medicines that target somehow altered protein activities. Recently, Vivoryon revealed an important selection for a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024. This event, scheduled for late October in San Diego, brings together leading experts in nephrology.
Details of the Presentation
Vivoryon's presentation will focus on the abstract titled, “Varoglutamstat Increases Glomerular Filtration in Elderly Patients without Signs of Proteinuria and Potentially Offers a New Approach to Treat Diabetic Kidney Disease (DKD).” This important discussion is set for October 25, from 5:40 PM to 5:50 PM, in Room 6C at the Convention Center. The presenting author will be Frank Weber, M.D., the CEO of Vivoryon, who expressed great enthusiasm about sharing their groundbreaking findings with fellow scientists and medical professionals.
Understanding Varoglutamstat's Role
At the heart of the presentation is Varoglutamstat (PQ912), a highly selective inhibitor of human glutaminyl cyclases QPCT and QPCTL. This molecule has shown remarkable therapeutic potential across several severe conditions, including inflammatory and fibrotic diseases, neurodegenerative disorders, and cancer. The company initially focused on Alzheimer's disease (AD) treatment, conducting numerous clinical trials that have validated the safety and tolerability of Varoglutamstat.
The VIVIAD Study Insight
In a recent Phase 2 study completed, termed VIVIAD, researchers explored kidney function alongside the effects of Varoglutamstat on biomarkers of kidney inflammation and fibrosis. While the selected participants primarily had AD, many also experienced reduced kidney functions due to age-related issues and comorbidities. This intersection of AD and kidney disease highlights the compound's potential in addressing both conditions effectively.
About Vivoryon Therapeutics N.V.
Vivoryon Therapeutics is on a mission to revolutionize treatment options for patients suffering from various severe diseases. The company specializes in developing small molecule-based medicines that modulate protein functionality altered in pathological settings. With a solid commitment to innovative science, Vivoryon has built a strong pipeline featuring several oral small molecule inhibitors targeting Alzheimer’s disease, kidney conditions, and other serious health issues.
A Vision for Innovative Solutions
The team at Vivoryon Therapeutics is not only about developing drugs but also about leading the way to change lives. Their in-depth understanding of post-translational modifications enables them to create impactful solutions that could change the standard care for countless patients worldwide. As research continues and the results from ASN Kidney Week unfold, the excitement surrounding Varoglutamstat’s potential to treat kidney disease only grows.
Frequently Asked Questions
What is Varoglutamstat?
Varoglutamstat (PQ912) is a selective inhibitor that targets specific enzymes involved in pathological protein modifications, showing promise in treating conditions like Alzheimer's disease and diabetic kidney disease.
Where will the ASN Kidney Week 2024 take place?
The ASN Kidney Week 2024 will be held in San Diego, offering a platform for discussing cutting-edge nephrology research.
Who will present the findings?
Frank Weber, M.D., the CEO of Vivoryon, is set to present the findings related to Varoglutamstat's effects on kidney filtration in elderly patients.
What was the VIVIAD study about?
The VIVIAD study investigated the effects of Varoglutamstat on kidney function and aimed to assess its impact on biomarkers related to kidney inflammation and fibrosis in Alzheimer's patients.
What are Vivoryon's goals?
Vivoryon aims to develop novel small molecule-based therapies and significantly improve the treatment landscape for patients suffering from severe diseases.
